Join to View Full Profile
1 Medical Center DrBiddeford, ME 04005
Phone+1 207-294-5800
Dr. Rubin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
University of Calgary Faculty of MedicineClass of 1988
Certifications & Licensure
NJ State Medical License 1973 - Present
IA State Medical License 2023 - 2025
ME State Medical License 2016 - 2025
NH State Medical License 2017 - 2025
NC State Medical License 1993 - 2021
NY State Medical License 2014 - 2016
WA State Medical License 1993 - 2015
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
- Tesetaxel as First-line Therapy for Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsRe: Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):91...Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani
Journal of Surgical Oncology. 2017-07-28 - 70 citationsUsing the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani
Journal of Surgical Oncology. 2017-06-01 - 2 citationsPhase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancerHelen K. Chew, Lee S. Schwartzberg, Suprith Badarinath, Peter Rubin, Grace Shumaker
Springerplus. 2014-02-22
Press Mentions
Number of Cancer Clinical Trials to Triple in Maine as NCROP Infuses $5.1M into Maine Health Cancer Care Network (MNCCN)October 7th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
